Rheumatoid Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 74 years old with moderate to severe active rheumatoid arthritis, for whom a doctor has prescribed the medication filgotinib in line with the approved product guidelines.
- People who are right-handed (this requirement helps keep brain imaging results consistent across participants).
Who may not be able to join:
- People who are not able to give written consent to participate.
- People with serious physical disabilities, such as blindness, deafness, or paralysis.
- People who are pregnant or breastfeeding.
- People with severe claustrophobia (fear of enclosed spaces) that would prevent them from having an MRI scan.
- People who have a medical reason why an MRI scan would not be safe for them.
- People who have a major neurological condition such as multiple sclerosis, stroke, or a serious brain injury.
- People who have previously been treated with certain targeted medicines for rheumatoid arthritis, such as baricitinib or tofacitinib (this type of medication is known as a targeted synthetic DMARD).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Neil Basu, MD, PhD, University of Glasgow
Phone: 0141 330 8388
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate the effects of Filgotinib in RA on CNS pain sensitisation (as measured by MRI brain) for DMN-Insula fMRI brain connectivity at 12 weeks.; To evaluate the effects of Filgotinib in RA on CNS pain sensitisation (as measured by MRI brain) for insular glutamate levels at 12 weeks.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.